Our Technology Partnering Interests
Our Technology Partnering Interests
Search
Your Guide to Partnering with Us
Your Guide to Partnering with Us
The Research Process
The Research Process
NVSS: The Future Vets & Scientists | Boehringer Ingelheim US
Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
Therapeutics
Therapeutics
Duluth, Georgia
Boehringer Ingelheim Animal Health employs about
Our Research Beyond Borders Partnering Interests
Our Research Beyond Borders Partnering Interests
Our Central Nervous System Partnering Interests
Our Central Nervous System Partnering Interests
Contact Us
Contact Us
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Sustainable Development - Our Commitment
Our Commitment
Horses
Horses
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide
Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.
Oncology Partnering Interests | Boehringer Ingelheim US
Click here to view our range of downloads on Boehringer Ingelheim's oncology & cancer immunology partnering interests.
More Potential
More Potential
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
New initiative elevates the importance of CKD testing
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
CIA Reporting Requirements
CIA Reporting Requirements
Corporate Profile
Corporate Profile